Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer

被引:75
作者
De Salins, A. Guyot D'Asnieres [1 ]
Tachon, G. [2 ,3 ,4 ]
Cohen, R. [5 ]
Karayan-Tapon, L. [2 ,3 ,4 ]
Junca, A. [6 ]
Frouin, E. [6 ]
Godet, J. [6 ]
Evrard, C. [6 ]
Randrian, V [1 ,2 ]
Duval, A. [8 ]
Svrcek, M. [8 ,9 ]
Lascols, O. [8 ]
Vignot, S. [5 ]
Coulet, F. [10 ,11 ]
Andre, T. [5 ,8 ]
Flejou, J-F [8 ,9 ]
Cervera, P. [8 ,9 ]
Tougeron, D. [1 ,2 ,7 ]
机构
[1] Univ Poitiers Hosp, Gastroenterol Dept, 2 Rue Miletrie, F-86021 Poitiers, France
[2] Univ Poitiers, Fac Med, Poitiers, France
[3] Univ Poitiers, Expt & Clin Neurosci Lab, INSERM 1084, Poitiers, France
[4] Univ Poitiers Hosp, Canc Biol Dept, Poitiers, France
[5] Sorbonne Univ, Dept Med Oncol, St Antoine Hosp, AP HP, Paris, France
[6] Univ Poitiers Hosp, Pathol Dept, Poitiers, France
[7] Univ Poitiers Hosp, Med Oncol Dept, Poitiers, France
[8] Sorbonne Univ, INSERM,Equipe Labellisee Ligue Natl Canc, Unite Mixte Rech Sci 938 & SIRIC CURAMUS, Ctr Rech St Antoine,Equipe Instabilite Microsatel, Paris, France
[9] Sorbonne Univ, St Antoine Hosp, AP HP, Dept Pathol, Paris, France
[10] Hop La Pitie Salpetriere, AP HP, Dept Genet, Paris, France
[11] Sorbonne Univ, Paris, France
关键词
colorectal cancer; microsatellite instability; deficient mismatch repair; immunohistochemistry; molecular biology; LYNCH-SYNDROME; MONONUCLEOTIDE REPEATS; IMMUNOHISTOCHEMISTRY; RISK; PREDISPOSITION; INDIVIDUALS; DEFICIENT; MUTATIONS; NIVOLUMAB; UTILITY;
D O I
10.1016/j.esmoop.2021.100120
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: DNA mismatch repair system deficiency (dMMR) is found in 15% of colorectal cancers (CRCs). Two methods are used to determine dMMR, immunohistochemistry (IHC) of MMR proteins and molecular testing of microsatellite instability (MSI). Only studies with a low number of patients have reported rates of discordance between these two methods, ranging from 1% to 10%. Materials and methods: Overall, 3228 consecutive patients with CRCs from two centers were included. Molecular testing was carried out using the Pentaplex panel and IHC evaluated four (MLH1, MSH2, MSH6, and PMS2; cohort 1; n = 1085) or two MMR proteins (MLH1 and MSH2; cohort 2; n = 2143). The primary endpoint was the rate of discordance between MSI and MMR IHC tests. Results: Fifty-one discordant cases (1.6%) were initially observed. Twenty-nine out of 51 discordant cases were related to IHC misclassifications. In cohort 1, after re-reading IHC and/or carrying out new INC, 16 discordant cases were reclassified as nondiscordant. In cohort 2, after the addition of MSH6/PMS2 IHC and re-examination, 13 were reclassified as nondiscordant. In addition, 10 misclassifications of molecular tests were identified. Finally, only 12 discordant cases (0.4%) remained: 5 were proficient MMR/MSI and 7 were dMMR/microsatellite stable. Conclusions: Our study confirmed the high degree of concordance between MSI and MMR IHC tests. Discordant cases must be reviewed, and if needed, tests must be repeated and analyzed by an expert team.
引用
收藏
页数:9
相关论文
共 56 条
  • [21] MSIplus for Integrated Colorectal Cancer Molecular Testing by Next-Generation Sequencing
    Hempelmann, Jennifer A.
    Scroggins, Sheena M.
    Pritchard, Colin C.
    Salipante, Stephen J.
    [J]. JOURNAL OF MOLECULAR DIAGNOSTICS, 2015, 17 (06) : 705 - 714
  • [22] Jaffrelot M, 2019, ANN ONCOL, V30, P807
  • [23] KIM HG, 1994, AM J PATHOL, V145, P148
  • [24] A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer
    Kim, Jwa Hoon
    Kim, Sun Young
    Baek, Ji Yeon
    Cha, Yong Jun
    Ahn, Joong Bae
    Kim, Han Sang
    Lee, Keun-Wook
    Kim, Ji-Won
    Kim, Tae-You
    Chang, Won Jin
    Park, Joon Oh
    Kim, Jihun
    Kim, Jeong Eun
    Hong, Yong Sang
    Kim, Yeul Hong
    Kim, Tae Won
    [J]. CANCER RESEARCH AND TREATMENT, 2020, 52 (04): : 1135 - 1144
  • [25] Interobserver variability in the evaluation of mismatch repair protein immunostaining
    Klarskov, Louise
    Ladelund, Steen
    Holck, Susanne
    Roenlund, Karina
    Lindebjerg, Jan
    Elebro, Jacob
    Halvarsson, Britta
    von Salome, Jenny
    Bernstein, Inge
    Nilbert, Mef
    [J]. HUMAN PATHOLOGY, 2010, 41 (10) : 1387 - 1396
  • [26] PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
    Le, D. T.
    Uram, J. N.
    Wang, H.
    Bartlett, B. R.
    Kemberling, H.
    Eyring, A. D.
    Skora, A. D.
    Luber, B. S.
    Azad, N. S.
    Laheru, D.
    Biedrzycki, B.
    Donehower, R. C.
    Zaheer, A.
    Fisher, G. A.
    Crocenzi, T. S.
    Lee, J. J.
    Duffy, S. M.
    Goldberg, R. M.
    de la Chapelle, A.
    Koshiji, M.
    Bhaijee, F.
    Huebner, T.
    Hruban, R. H.
    Wood, L. D.
    Cuka, N.
    Pardoll, D. M.
    Papadopoulos, N.
    Kinzler, K. W.
    Zhou, S.
    Cornish, T. C.
    Taube, J. M.
    Anders, R. A.
    Eshleman, J. R.
    Vogelstein, B.
    Diaz, L. A., Jr.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (26) : 2509 - 2520
  • [27] Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164
    Le, Dung T.
    Kim, Tae Won
    Van Cutsem, Eric
    Geva, Ravit
    Jager, Dirk
    Hara, Hiroki
    Burge, Matthew
    O'Neil, Bert
    Kavan, Petr
    Yoshino, Takayuki
    Guimbaud, Rosine
    Taniguchi, Hiroya
    Elez, Elena
    Al-Batran, Salah-Eddin
    Boland, Patrick M.
    Crocenzi, Todd
    Atreya, Chloe E.
    Cui, Yi
    Dai, Tong
    Marinello, Patricia
    Diaz, Luis A., Jr.
    Andre, Thierry
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (01) : 11 - +
  • [28] Acquired somatic MMR deficiency is a major cause of MSI tumor in patients suspected for "Lynch-like syndrome" including young patients
    Lefol, Cedrick
    Sohier, Emilie
    Baudet, Christian
    Naibo, Pierre
    Ruano, Eric
    Grand-Masson, Chloe
    Viari, Alain
    Wang, Qing
    [J]. EUROPEAN JOURNAL OF HUMAN GENETICS, 2021, 29 (03) : 482 - 488
  • [29] Clinicopathologic Risk Factor Distributions for MLH1 Promoter Region Methylation in CIMP-Positive Tumors
    Levine, A. Joan
    Phipps, Amanda I.
    Baron, John A.
    Buchanan, Daniel D.
    Ahnen, Dennis J.
    Cohen, Stacey A.
    Lindor, Noralane M.
    Newcomb, Polly A.
    Rosty, Christophe
    Haile, Robert W.
    Laird, Peter W.
    Weisenberger, Daniel J.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2016, 25 (01) : 68 - 75
  • [30] Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors
    Lindor, NM
    Burgart, LJ
    Leontovich, O
    Goldberg, RM
    Cunningham, JM
    Sargent, DJ
    Walsh-Vockley, C
    Petersen, GM
    Walsh, MD
    Leggett, BA
    Young, JP
    Barker, MA
    Jass, JR
    Hopper, J
    Gallinger, S
    Bapat, B
    Redston, M
    Thibodeau, SN
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (04) : 1043 - 1048